
    
      To collect and assess data on the therapeutic potential of the NASVAC in CHB patients
      regarding:

      Reduction of the serum HBV DNA levels. Reduction in the levels of alanine aminotransferase
      (ALT) Clearance of hepatitis B e antigen (HBeAg) Negativation or lowering of HBsAg
      Anti-HBsAg/anti-HBeAg seroconversion

      An additional objective of this study is to reconfirm the safety of NASVAC in CHB patients
      that has previously been shown by us in Phase I-II clinical trial in CHB patients.
    
  